Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients Understanding non metastatic castration resistant prostate cancer with Dr. Hamilton A discussion on the characteristics and differences among castration-sensitive, nonmetastatic castration-resistant, and metastatic
Ravi Madan, MD, National Cancer Institute, Bethesda, MD, discusses the barriers to treatment intensification in metastatic Triplet therapy is abiraterone or darolutamide plus docetaxel and androgen deprivation therapy (ADT) in overall patient population. Triplet
What is New for the Prostate Cancer Patient with Non Metastatic Castration Resistant Prostate Cancer Treatment options for patients with metastatic castration-resistant prostate cancer
Living with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): Ron and Laurie's story How We Treat Metastatic Castration-Sensitive Prostate Cancer PCRI's executive director, Mark Scholz, MD, gives an overview of the Low-Royal stage of prostate cancer (that is, cancer that has
Triplet Therapy for Metastatic Hormone-sensitive Prostate Cancer Enhancing patient conversations about PARP inhibitors for mCRPC In this activity, a multidisciplinary team and patient advocate
Castrate Resistant, Non-Metastatic Prostate Cancer (M0 state) | Prostate Cancer Staging Guide Reporting from 2021 ASCO Annual Meeting, Primo "Lucky" Lara reports on positive results from the VISION study testing the Dr. Chi on the TITAN Trial Results in Metastatic Castration-Sensitive Prostate Cancer
Kurt Miller, MD, Phd, from Charité University Hospital, Berlin, Germany, discusses the combination of chemotherapy and hormone Data for Metastatic Castration-Sensitive Prostate Cancer Management of Patients with Metastatic Castration-Sensitive Prostate Cancer
The panelists, Raoul S. Concepcion, MD, FACS; Michael Fabrizio, MD, FACS; Jorge A. Garcia, MD, FACP; Charles J. Ryan, MD; Kim N. Chi, MD, a professor at the University of British Columbia and a medical oncologist at BC Cancer Vancouver, discusses the For more information, visit
PARP inhibitors for metastatic castration-resistant prostate cancer 7 CRPC portends poor outcomes with a mean survival time of about 30 months in the metastatic setting.8 As new agents demonstrated therapeutic Copy of Dr. Burgess on Key Data in Metastatic Castration-Sensitive Prostate Cancer
Apalutamide Combination is Well Tolerated in Metastatic Castration-Sensitive Prostate Cancer Ron and his wife, Laurie, discuss how finding the right treatment has helped keep Ron's prostate cancer from advancing. To learn Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance
Live from ASCO: Apalutamide for Castration-Sensitive Prostate Cancer Mayo Clinic is leading the way with a new treatment for advanced prostate cancer, specifically for prostate-specific membrane First-line Systemic Treatment Options for Metastatic Castration
Prostate cancer that needs androgens (male hormones) to grow and therefore stops growing when androgens are not present. In this CME Outfitters podcast, expert faculty focus on patient selection criteria for second-generation antiandrogen therapy and In conclusion, among men with newly diagnosed, metastatic, castration-sensitive prostate cancer, the addition of abiraterone plus prednisone to
Christos Kyriakopoulos, MD, University of Wisconsin, Madison, WI, reflects on the findings of the CHAARTED2 trial Dr. Burgess on Key Data in Metastatic Castration-Sensitive Prostate Cancer Dr. Agarwal on Drug Development in Metastatic Castration-Sensitive Prostate Cancer
Hormone-Sensitive Metastatic Prostate Cancer Treating Non-Metastatic Castrate Resistant Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MD
Andrew Ruplin, PharmD, clinical instructor and oncology clinical pharmacist at Seattle Cancer Care Alliance and the University of Dr. Stiles discusses castrate-resistant prostate cancer. Dr. Stiles discusses a few considerations for those planning on having Dr. Agarwal on the QoL With Apalutamide in Metastatic Castration-Sensitive Prostate Cancer
Dr. Yu on the Future of Castration-Sensitive Prostate Cancer PCRI's Alex asks Dr. Mark Scholz, a medical oncologist specializing in prostate cancer, all about the "M Zero" (M0) stage of The Differences Between mCRPC and nmCRPC
Professor Kurt Miller chairs a discussion with Professor Silke Gillessen, Professor Heather Payne and Dr Eric Small on the latest Dr. Hwang on Treatment Selection in Metastatic Castration-Sensitive Prostate Cancer Definition of castrate-sensitive prostate cancer - NCI Dictionary of
Jorge Garcia, MD, distinguishes between hormone-sensitive and castration-resistant disease in men with metastatic prostate Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Gwenaëlle Gravis Mescam, MD, Institut Paoli Calmettes, Marseille, France, comments on the subset of patients with metastatic Treating Non-Metastatic Castration Sensitive Prostate Cancer Current standards for first-line metastatic hormone-sensitive prostate cancer
The panelists discuss the evolution of treatment for patients with mCRPC, from the introduction of docetaxel to the advent of newer Emerging management of metastatic castration-sensitive prostate cancer: front-line chemotherapy Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains which metastatic
The changing landscape: Understanding non-metastatic (m0) castration resistant prostate cancer This presentation takes a closer Episode 154: New Drug Approvals for Metastatic Castration-Sensitive Prostate Cancer Join Drs. Sternberg and Oh. Download resources & collect credit » cmeo.me/pd065encore.
A New Treatment for Stage 4 Metastatic Prostate Cancer Chemo, Hormone Therapy, and Radiation For Advanced Metastatic #ProstateCancer #MarkScholzMD #PCRI Metastatic Castrate-Resistant Prostate Cancer: Options and Possible Sequences
Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to Metastatic castration-resistant prostate cancer – New learnings and perspectives In this webinar: Join CCSN and Dr. Hamilton for this educational session aimed at raising awareness of this subset of prostate
Management of Patients with Metastatic Castration-Sensitive Prostrate Cancer Abiraterone in metastatic castration-sensitive prostate cancer
Metastatic castration-sensitive prostate cancer (CSPC) can be treated with hormone therapy, radiation therapy and chemotherapy. Castration Resistant #ProstateCancer | #MarkScholzMD #PCRI Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology
Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer. View Topic. Share. Font Size. Dr. A. Oliver Sartor discusses the treatment options and sequencing strategies for metastatic castrate-resistant prostate cancer Overview of systemic treatment for recurrent or metastatic castration
Treating Patients With Progressive Metastatic Castration-Resistant Prostate Cancer The role of triplet therapy in men with metastatic castration sensitive prostate cancer
Understanding Metastatic Castration-Resistant Prostate Cancer Treatment Landscape for Metastatic Castrate-Sensitive Prostate
How do you prognosticate metastatic castration sensitive prostate cancer? Speaker Name: Dr. Rettig Welcome to PrecisCa - Your Advances in non-metastatic castration-resistant prostate cancer Eleni Efstathiou, MD, PhD, comments on the shift to earlier use of chemotherapy and novel androgen receptor (AR)–targeted
Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the Dr. Yu on Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer
Updates on non-metastatic castration-resistant prostate cancer How do you prognosticate metastatic castration sensitive prostate cancer? New hope for patients with metastatic prostate cancer
Kim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University Recent developments in treatment options for castration-sensitive metastatic prostate cancer The most advanced stage of prostate cancer is called metastatic castrate-resistant prostate cancer, when the cancer has spread to
Paul Monk, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses the treatments for patients with FDA approves darolutamide for metastatic castration-sensitive for metastatic castration-sensitive prostate cancer (mCSPC). The FDA previously approved darolutamide in combination with docetaxel for
Progression of Metastatic Prostate Cancer Defined Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses pivotal clinical trials in
Shell Liang, PhD, discusses metastatic castration-resistant prostate cancer (mCRPC), which does not respond to androgen The treatment of metastatic castration-sensitive prostate cancer (mCSPC) has seen remarkable breakthroughs over the last few years.
Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Learn more at Prof. de Wit (NL) talks about his lecture "Metastatic castration-resistant prostate cancer – New learnings and perspectives" at
Website: Twitter: Facebook: LinkedIn: In this insightful discussion, the Oncology Brothers and Dr. Alan Bryce address treatment strategies for non-metastatic Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Expert Video Report on castration sensitive and resistant prostate cancer - 2021 ASCO Annual Meeting A Case of Metastatic Castration-Resistant Prostate Cancer
Treatment intensification in metastatic castration-sensitive prostate cancer About Metastatic Castrate-Resistant Prostate Cancer Karim Fizazi, MD, PhD, Institut Gustave Roussy, Villejuif, France, describes the Phase III PEACE-1 trial (NCT01957436) of
Treatments for metastatic castration-sensitive prostate cancer Prof Jorge Garcia speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Kim Chi, M.D., author of the TITAN trial, explains the results of this double-blind, phase 3 trial that tested whether the addition of
Evolution of Treatment for Metastatic Castration-Resistant Prostate Cancer Pedro C. Barata, MD, MSc, reviews the case of a 69-year-old man who presents with and is treated for metastatic Emmanuel Seront, MD, PhD, Jolimont Hospital, La Louvière, Belgium, reviews advances in non-metastatic castration-resistant
Dr. Michael Morris, MD, Prostate Cancer Section Head at MSK, explains the use of theranostics as a new treatment for people with Abiraterone plus Prednisone in Metastatic, Castration-Sensitive
Donate to PCRI: For more information, visit 0:22 Which prostate cancer patients are most The treatment landscape for metastatic castration-sensitive prostate cancer (mCSPC) has rapidly evolved over the past 5 years. Castrate resistant prostate cancer